Inventor · disambiguated record
Jose F. Ponte
Also filed as: PONTE JOSE · PONTE JOSE F
14 granted patents·11 pending applications·1,432 citations·filing 2006–2024
94Inventor score
Top patents by PatentIndex Score
25 records- 0197US8591886B2Combination therapies employing GITR binding moleculesPONATH PAUL·Filed 2008·Granted Nov 26, 2013·399 cites·10 claims
- 0296US9028823B2Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodiesGITR INC·Filed 2013·Granted May 12, 2015·77 cites·20 claims
- 0396US8388967B2Methods for inducing or enhancing an immune response by administering agonistic GITR-binding antibodiesSMITH L MARY·Filed 2010·Granted Mar 5, 2013·422 cites·34 claims
- 0496US7812135B2GITR-binding antibodiesTOLERRX INC·Filed 2006·Granted Oct 12, 2010·450 cites·27 claims
- 0594US9241992B2Combination therapies employing GITR binding moleculesGITR INC·Filed 2013·Granted Jan 26, 2016·22 cites·19 claims
- 0692US11033564B2Therapeutic combinations comprising anti-FOLR1 immunoconjugatesIMMUNOGEN INC·Filed 2018·Granted Jun 15, 2021·8 cites·24 claims
- 0792US10172875B2Therapeutic combinations comprising anti-FOLR1 immunoconjugatesIMMUNOGEN INC·Filed 2016·Granted Jan 8, 2019·9 cites·25 claims
- 0891US7777008B2ILT3 binding molecules and uses thereforTOLERX INC·Filed 2007·Granted Aug 17, 2010·19 cites·28 claims
- 0990US11395796B2Anti-CD37 immunoconjugate and anti-CD20 antibody combinationsDEBIOPHARM INT SA·Filed 2018·Granted Jul 26, 2022·5 cites·10 claims
- 1090US9493572B2GITR antibodies and methods of inducing or enhancing an immune responseGITR INC·Filed 2015·Granted Nov 15, 2016·7 cites·21 claims
- 1187US8901281B2ILT3 binding molecules and uses thereforPONATH PAUL·Filed 2006·Granted Dec 2, 2014·13 cites·22 claims
- 1280US2024368270A1Anti-folr1 immunoconjugate regimensIMMUNOGEN INC·Filed 2024·Application pending·0 cites
- 1376US10030074B2Methods of inducing or enhancing an immune response in a subject having cancer by administering GITR antibodiesGITR INC·Filed 2016·Granted Jul 24, 2018·1 cites·21 claims
- 1475US12239732B2Anti-CD37 immunoconjugate and anti-CD20 antibody combinationsDEBIOPHARM INT SA·Filed 2022·Granted Mar 4, 2025·0 cites·12 claims
- 1573US2022168326A1Therapeutic combinations comprising anti-folr1 immunoconjugatesIMMUNOGEN INC·Filed 2022·Application pending·0 cites
- 1669US2015132323A1Anti-FOLR1 Immunoconjugate Dosing RegimensIMMUNOGEN INC·Filed 2014·Application pending·0 cites
- 1767US2021155688A1Anti-folr1 immunoconjugate dosing regimensIMMUNOGEN INC·Filed 2021·Application pending·0 cites
- 1866US10570209B2Methods for inducing or enhancing an immune response by administering agonistic glucocorticoid-induced TNFR-family-related receptor (GITR) antibodiesGITR INC·Filed 2018·Granted Feb 25, 2020·0 cites·22 claims
- 1966US2020397806A1Therapeutic combinations comprising anti-folr1 immunoconjugatesIMMUNOGEN INC·Filed 2020·Application pending·0 cites
- 2059US2019030162A1Combination Therapies Employing GITR Binding MoleculesGITR INC·Filed 2018·Application pending·0 cites
- 2158US2015139986A1Ilt3 binding molecules and uses thereforMERCK SHARP & DOHME·Filed 2014·Application pending·0 cites
- 2255US2017000900A1Anti-cd37 immunoconjugate and anti-cd20 antibody combinationsIMMUNOGEN INC·Filed 2016·Application pending·0 cites
- 2353US2016324963A1Combination therapies employing gitr binding moleculesGITR INC·Filed 2015·Application pending·0 cites
- 2445US2011034675A1Ilt3 Binding Molecules And Uses ThereforTOLERX INC·Filed 2010·Application pending·0 cites
- 2535US2015297744A1Anti-FOLR1 Immunoconjugate Dosing RegimensIMMUNOGEN INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jose F. Ponte files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →